1.
|
Details of PDMR/person closely associated with them ('PCA')
| ||||
a)
|
Name
|
Dr H Barron
| |||
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
| |||
c)
|
Initial notification/
amendment
|
Initial notification
| |||
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
|
Name
|
GlaxoSmithKline plc
| |||
b)
|
LEI
|
5493000HZTVUYLO1D793
| |||
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
| ||||
a)
|
Description of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b)
|
Nature of the transaction
|
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account
| |||
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
| ||
$39.28
|
1,273.113
| ||||
d)
|
Aggregated information
|
N/A (single transaction)
| |||
Aggregated volume Price
| |||||
e)
|
Date of the transaction
|
2021-09-22
| |||
f)
|
Place of the transaction
|
New York Stock Exchange (XNYS)
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 24 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2021 18:11:10 UTC.